Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lamivudine Indinavir

Drugs that may affect nelfinavir include anticonvulsants, azithromycin, azole antifungals, efavirenz, delavirdine, HMG-CoA reductase inhibitors, indinavir, interleukins, nevirapine, rifabutin, rifampin, ritonavir, saquinavir, St. John s wort. Drugs that may be affected by nelfinavir include amiodarone, antiarrhythmics (amiodarone, quinidine), azithromycin, benzodiazepines, efavirenz, ergot alkaloids, delavirdine, didanosine, fentanyl, indinavir, lamivudine methadone, nonsedating antihistamines, oral contraceptives, phenytoin, pimozide, quinidine, rifabutin, saquinavir, sildenafil, sirolimus, tacrolimus, zidovudine. [Pg.1820]

Zidovudine Fosamprenavir, indinavir, lamivudine Didanosine, nelfinavir, ritonavir... [Pg.1077]

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, TorteU S, CutreU A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults A randomized equivalence trial. JAMA 2001 285(9) 1155-63. [Pg.1738]

An HIV-positive patient taking methadone 90 mg daily with indinavir, lamivudine and zidovudine, developed withdravral symptoms and was hospitalised within a week of stopping these HIV drugs and starting ritonavir 400 mg, saquinavir 400 mg and stavudine 40 mg twice daily. The patient was eventually re-stabilised taking methadone 130 mg daily. ... [Pg.182]

No clinically significant interaction appears to occur between adefovir and co-trimoxazole, didanosine, delavirdine, efavirenz, ibuprofen, indinavir, lamivudine, nelfinavir, nevirapine, paracetamol, tenofovir, or zidovudine. Adefovir possibly reduces saquinavir levels. [Pg.775]

Shulman NS, Bosch RJ, MeUors JW, Albrecht MA, Katzenstein DA (2004) Genetic correlates of efavirenz hypersusceptibility. AIDS 13 1781-1785 Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DE, Earina D et al (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341 1865-1873 SteUbrink HJ (2007) Antiviral drugs in the treatment of AIDS what is in the pipeline Eur J Med Res 12 483 95... [Pg.175]

Zidovudine Didanosine Stavudine Lamivudine Abacavir Tenofovir Emtricitabine Nevirapine Efavirenz TMC125 Saquinavir Indinavir Lopinavir Fosamprenavir Atazanavir Tipranavir Darunavir Raltegravir Elvitegravir Enluvirtide Maraviroc Vicriviroc Bevirimat... [Pg.335]

Drugs that should not be combined due to overlapping toxi-cities include amprenavir oral solution plus ritonavir oral solution, atazanavir plus indinavir (due to enhanced hyperbilirubinemia), and any combination of didanosine, stavudine, and zalcitabine. Emtricitabine and lamivudine should not be combined because of their similar chemical structures, and antagonism can result when lamivudine is combined with zalcitabine, or stavudine is combined with zidovudine. [Pg.1259]

TC, lamivudine ABC, abacavir APV, amprenavir AST, aspartate aminotransferase ALT, alanine aminotransferase ATV, atazanavir CBC, complete blood cell count D/C, discontinue ddl, didano-sine d4T, stavudine EFV, efavirenz FTC, emtricitabine P1BV, hepatitis B virus F1CV, hepatitis C vims HIV, human immunodeficiency virus IDV, indinavir IV, intravenous LFT, liver function tests LPV/r, lopinavir + ritonavir NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor PT, prothrombin time T.bili, total bilirubin TDF, tenofovir disoproxiI fumarate TPV, tipranavir ULN, upper limit of normal ZDV, zidovudine. [Pg.1271]

TC Lamivudine ABC Abacavir d4T Stavudine ddC Zalcitabine ddl Didanosine TDF Tenofovir ZDV Zidovudine, also abbreviated as AZT FTC Emtricitabine NVP Nevirapine DLV Delavirdine EFV Efavirenz RTV, r Ritonavir Pl/r Ritonavir boosted protease inhibitor SQV Saquinavir IDV Indinavir LPV Lopinavir NEV Nelfinavir APV Amprenavir ATV Atazanavir DRV Darunavir... [Pg.550]

Gulick RM, Mellors JW, Havilir D, Eron JJ, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. NEJM. 337 734-739. [Pg.198]

Sataszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. NEJM. 341 1865-1873. [Pg.200]

While this pattern of biochemistry does not exclude transient relapse of Graves hyperthyroidism (despite the finding of negative TSH receptor antibodies), or a transient thyroiditis, the authors speculated that indinavir (prescribed in this patient together with stavudine and lamivudine) had inhibited the glucuronidation of thyroxine and hence caused a rise in serum thyroid hormone concentrations. [Pg.352]

The effects of the protease inhibitor indinavir and the NNRTI efavirenz on lipid concentrations have been compared in a large comparative randomized study (154). Each of the two comparison drugs were used in one arm (with a zidovudine + lamivudine backbone) and the combination of the two drugs in a third arm. Zidovudine and lamivudine did not play a role in the lipid changes. However, both of the comparison drugs significantly increased cholesterol concentrations. [Pg.583]

A 37-year-old HIV-infected woman receiving stavudine, lamivudine, and indinavir developed epigastric pain, anorexia, and vomiting. She had lactic acidosis (serum lactate 4.9 mmol/1), raised liver enzymes, and an increased prothrombin time. She had hepatomegaly and tachypnea and required mechanical ventilation. Her progress was complicated by pancreatitis and acute respiratory distress syndrome. Antiviral medication was stopped and she was treated with co-enzyme Q, carnitine, and vitamin C. The serum lactic acid and transaminases returned to normal over 4 weeks and she was weaned off the ventilator after 4 months. [Pg.631]

At the present time, there are at least 14 compounds that have been formally approved for the treatment of human immunodeficiency virus (HIV) infections. There are six nucleoside reverse transcriptase inhibitors (NRTIs) that, after their intracellular conversion to the 5 -triphosphate form, are able to interfere as competitive inhibitors of the normal substrates (dNTPs). These are zidovudine (AZT), didanosine (ddl), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), and abacavir (ABC). There are three nonnucleoside reverse transcriptase inhibitors (NNRTIs) — nevirapine, delavirdine, and efavirenz — that, as such, directly interact with the reverse transcriptase at a nonsubstrate binding, allosteric site. There are five HIV protease inhibitors (Pis saquinavir, ritonavir, indinavir, nelfinavir, and amprenavir) that block the cleavage of precursor to mature HIV proteins, thus impairing the infectivity of the virus particles produced in the presence of these inhibitors. [Pg.387]

HIV infection Health care workers exposed to blood after needle-stick injury Zidovudine and lamivudine indinavir or nelfinavir Good... [Pg.1188]

Indinavir sulfate is a protease inhibitor and is used in combinations for the treatment of viral infection. During the high risk of HIV infection, indinavir is combined with zidovudine and lamivudine.65 Indinavir sulfate should be used with caution in patients with hepatic impairment and avoided in patients with severe liver damage. Caution is needed in diabetic patients and in patients with hemophilia. Adverse effects of indinavir sulfate include nausea, vomiting, diarrhea, fatigue, dizziness, headache, skin rashes, and allergic reactions (hematuria). [Pg.294]

A 36-year-old HIV-positive man taking zidovudine, lamivudine, and indinavir was noticed to have a mild asymptomatic anemia (hemoglobin 10.2 g/1, white cell count 10.4 x 109/1 with a normal differential count, and platelets 237 x 109/1). The blood film suggested hemolysis. He had taken ecstasy 2 weeks earlier for the first time. The anemia was reportedly secondary to oxidative stress, probably due to drug toxicity. Three weeks later his hemoglobin returned to normal. [Pg.603]

Morales-Ramirez J, Tashima K, Hardy D, et al. In A phase III, multicenter randomized open-label study to compare the antiretroviral activity and tolerability of efa-virenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 36 weeks (DMP 266-006)38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington DC American Society for Microbiology, 1998 1-103. [Pg.707]

Preferred Pl-based regimens are lopinavir/ritonavir plus lamivudine or emtricitabine plus another NRTI, usually zidovudine, stavudine or abacavir. Alternative combinations include other Pis with or without ritonavir, and two NRTIs. The combination of a protease inhibitor with ritonavir provides inhibition of cytochrome p450 enzymes and permits less frequent dosing of amprenavir, indinavir, lopinavir and saquinavir. Use of ritonavir in this setting is also known as boosting. ... [Pg.610]

A 38-year-old man, who had taken amiodarone 200 mg/day for more than 6 months, was given postexposure prophylaxis for HIV infection after a needle injury this included zidovudine, lamivudine, and indinavir (256). During the 4 weeks of therapy his serum amiodarone concentration rose from 0.9 to 1.3 mg/1, with only a small rise in the serum concentration of desethylamiodarone from 0.4 to 0.5 mg/1. After withdrawal of the prophylactic therapy the plasma amiodarone concentration gradually fell to the pretreatment value, and there was no further change in the concentration of desethylamiodarone. [Pg.165]

A 35-year old Caucasian man with AIDS and multiple opportunistic infections, including Mycobacterium kansasii and Mycobacterium avium complex (MAC) disease developed moderate to severe primary sensorineural hearing loss after 4—5 months of therapy with oral azithromycin 500 mg/day. Other medications included ethambutol, isoniazid, rifabutin, ciprofloxacin, co-trimoxazole, fluconazole, zidovudine (later switched to stavudine), lamivudine, indinavir, methadone, mod-ified-release oral morphine, pseudoephedrine, diphenhydramine, megestrol acetate, trazodone, sorbitol, salbutamol by metered-dose inhaler and nebulizer, ipratropium, and oral morphine solution as needed. Significant improvement of the hearing impairment was documented 3 weeks after drug withdrawal. [Pg.390]

Failure of antiretroviral drug therapy has been attributed to an interaction of carbamazepine with indinavir in a 48-year-old man taking indinavir, zidovudine, and lamivudine his HIV-RNA viral load became undetectable after less than 2 months and he developed a Herpes zoster infection (87). Lower doses of carbamazepine are also required during co-administration of ritonavir, as has been shown in two recent cases. [Pg.633]

Efavirenz is a non-nucleoside reverse transcriptase inhibitor with excellent inhibitory activity against HTV-l. Its most frequent adverse effects involve the central nervous system and the skin (1). At the start of therapy, dizziness, insomnia, or fatigue is observed in most patients, and headache and even psychotic reactions have also been observed. A maculopapular rash is seen in about 10%. These adverse effects usually vanish within the first 2-4 weeks of therapy (2). About 1-2% of individuals stop taking efavirenz because of neurological or dermatological adverse events. Administration of efavirenz at bedtime reduces the incidence of severe adverse effects, and the rash can be managed by short-term antihistamines or topical corticosteroids (1). Nausea and vomiting are less often observed than in patients treated with zidovudine, lamivudine, or indinavir. [Pg.1204]

A 40-year-old man, who had taken stavudine 30 mg bd, lamivudine 150 mg bd, and indinavir 800 mg qds, developed an occipital headache, nausea, and vomiting. His blood pressure was 220/140 mmHg and he had bilateral papilledema. His blood pressure was controlled and his symptoms disappeared. An MRI scan of the brain showed lesions in the periventricular white matter the nuclei semiovale and occipital asta were most severely affected. Indinavir was withdrawn and replaced by nel-finavir his blood pressure returned to normal and the MRI white matter lesions disappeared. [Pg.1735]

A 36-year-old HIV-positive man had started to take zidovudine and zalcitabine 9 months earlier together with co-trimoxazole as primary prophylaxis against Pneumocystis jiroveci, but switched to indinavir, stavudine, and lamivudine. Two hours after the first dose of indinavir he developed a high fever, generalized myalgia, and malaise and started to vomit. After the second dose he developed shock and cyanosis. [Pg.1735]

A 35-year-old man, who had taken indinavir 2400 mg/day, lamivudine 300 mg/day, and stavudine 80 mg/day for 10 months, developed a slowly progressive paraparesis, with sensory disturbances in the legs. An MRI scan was consistent with epidural lipomatosis. On withdrawal of indinavir, the symptoms gradually resolved. [Pg.1735]


See other pages where Lamivudine Indinavir is mentioned: [Pg.82]    [Pg.82]    [Pg.1140]    [Pg.1107]    [Pg.212]    [Pg.82]    [Pg.82]    [Pg.1140]    [Pg.1107]    [Pg.212]    [Pg.305]    [Pg.1840]    [Pg.297]    [Pg.218]    [Pg.1108]    [Pg.297]    [Pg.584]    [Pg.1181]    [Pg.243]    [Pg.695]    [Pg.382]    [Pg.693]    [Pg.744]    [Pg.325]    [Pg.610]   
See also in sourсe #XX -- [ Pg.804 ]




SEARCH



Indinavir

© 2024 chempedia.info